Can the US–India Partnership Fix Cancer Drug Shortages? | Kathleen Jaeger скачать в хорошем качестве

Can the US–India Partnership Fix Cancer Drug Shortages? | Kathleen Jaeger

In this episode on OncoDaily TV, host Amalya Sargsyan, MD (VP, Research & Intelligence) speaks with Kathleen Jaeger, U.S. Spokeswoman for the Indian Pharmaceutical Alliance, about how U.S.–India (and Europe) collaboration on high-quality generics can strengthen oncology supply, reduce costs, and de-risk dependence on single-country sources for KSMs/APIs - while keeping FDA-level quality front and center. Key points ✅ Access & affordability: Generics make up ~90% of U.S. prescriptions and are typically ~80% cheaper, unlocking care for more patients. ✅ Global supply reality: India supplies ~50–60% of U.S. generics; chokepoints sit upstream in KSMs/APIs. ✅ De-risking from China: Policy focus is shifting to diversify sources for critical oncology inputs to prevent shortages. ✅ Quality first: FDA quality maturity metrics, unannounced inspections, and digital/AI oversight. ✅ Why shortages happen: Root causes ✅ Policy tools: Defense Production Act Title III, the U.S.–India “Trust” framework, and an Affordable Medicines Partnership. ✅ Clinician perspective: If FDA-approved and guideline-endorsed, generics/biosimilars offer the same safety/efficacy as brands. ✅ Health security: “Medicine security = national security”—resilient oncology supply chains are a public-interest imperative. 0:00 Introduction 2:10 Generics 101—access, affordability, impact 3:42 U.S. savings & utilization 4:20 COVID lessons: KSM/API dependence & India’s response 8:17 Quality safeguards & “lighthouse” facilities 11:26 Policy levers: DPA Title III, reshoring critical inputs 12:58 U.S.–India “Trust” framework → Affordable Medicines Partnership 15:19 Root causes of shortages 18:44 Clinician view: trust, guidelines, biosimilars 24:23 Tariffs vs incentives—what actually builds resiliency 26:30 What’s next: trade agreement, implementation, diversification 27:40 Health/medicine security as national security 30:05 Closing #Oncology #Generics #Biosimilars #DrugShortages #SupplyChain #APIs #KSMs #USIndia #FDA #Quality #CancerPolicy #Access #Affordability #OncoDaily SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/